Literature DB >> 16473646

Myelotoxicity from chemotherapy.

Davey Daniel1, Jeffrey Crawford.   

Abstract

Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16473646     DOI： 10.1053/j.seminoncol.2005.11.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  20 in total

1.  The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

Authors:  Kaustubh N Bhinge; Vineet Gupta; Salman B Hosain; Seetharama D Satyanarayanajois; Sharon A Meyer; Benny Blaylock; Qian-Jin Zhang; Yong-Yu Liu
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

Review 2.  Targeting breast cancer stem cells.

Authors:  Sean P McDermott; Max S Wicha
Journal:  Mol Oncol       Date:  2010-06-17       Impact factor: 6.603

Review 3.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

4.  The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress.

Authors:  C Marcela Diaz-Montero; Yong Wang; Lijian Shao; Wei Feng; Abdel-Aziz Zidan; Christopher J Pazoles; Alberto J Montero; Daohong Zhou
Journal:  Free Radic Biol Med       Date:  2012-02-15       Impact factor: 7.376

5.  The anti-hepatocellular carcinoma activity of Mel-P15 is mediated by natural killer cells.

Authors:  Tao Xu; Tongxing Cui; Lipan Peng; Shuai Kong; Jianqiang Zou; Xingsong Tian
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

6.  An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth.

Authors:  Toshihiko Tanno; Peng Zhang; Christopher A Lazarski; Yang Liu; Pan Zheng
Journal:  Blood Adv       Date:  2017-06-22

Review 7.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

8.  Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells.

Authors:  Xia Xiao; Hongmei Luo; Kenneth N Vanek; Amanda C LaRue; Bradley A Schulte; Gavin Y Wang
Journal:  Stem Cells Dev       Date:  2015-03-03       Impact factor: 3.272

9.  Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.

Authors:  Bikul Das; Roula Antoon; Rika Tsuchida; Shamim Lotfi; Olena Morozova; Walid Farhat; David Malkin; Gideon Koren; Herman Yeger; Sylvain Baruchel
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

10.  The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity.

Authors:  Jia Song; Tongtong Liu; Yue Yin; Wei Zhao; Zhiqiang Lin; Yuxin Yin; Dan Lu; Fuping You
Journal:  EMBO Rep       Date:  2021-01-04       Impact factor: 8.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.